Země: Izrael
Jazyk: angličtina
Zdroj: Ministry of Health
RAMIPRIL
TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL
C09AA05
TABLETS
RAMIPRIL 2.5 MG
PER OS
Required
TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL
RAMIPRIL
RAMIPRIL
Hypertension congestive heart failure reduction of mortality in patients after MI with left ventricular dysfunction For reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous MI unstable angina or multivessel CABG or multivessel PTCA) stroke or peripheral vascular disease. Also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : - hypertension (systolic blood pressure > 160 mmHg or diastolic pressure > 90 mmHg) - high total cholesterol (>5.2 mmol/L) - low HDL ( <0.9 mmol/L) - current smoker - known microalbuminuria - clinical evidence of previous vascular disease. Prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.
2015-01-31
דומע 1 ךותמ 4 _ _ _ _ _ :ךיראת_ _ ראוני_ _2018_ _ _ ה/דבכנ ת/חקור ,ה/ אפור ןולעב םיאבה םינוכדעה תא רשיא תואירבה דרשמש העידומ עבט תרבח אפורל/ןכרצל :רישכתה לש _ _ עבט לירפימר 5 ג"מ תוילבט RAMIPRIL TEVA 5 MG TABLETS CONTAINS : : ליעפה רמוחה תומכו םש _ _ _PER TABLETS_ _ _ _ _ _RAMIPRIL 5 MG_ ןכרצל ןולעב םינוכדע ------------------------------------------------------------------------------------------------------------ היוותה יפכ הרשואש תדועתב םושירה : - Hypertension - Congestive heart failure - Reduction of mortality in patients after MI with left ventricular dysfunction For reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous MI unstable angina or multivessel CABG or multivessel PTCA) stroke or peripheral vascular disease. Also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmHg or diastolic pressure > 90 mmHg) high total cholesterol (>5.2 mmol/L) low HDL ( <0.9 mmol/L) current smoker known microalbuminuria clinical evidence of previous vascular disease. - Prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day. ל ןולעהש עידוהל וננוצרב ןכדוע ןכרצ םיקזוח תרסהו תורמחה םע 2.5 ג"מ ו - 10 ןולעהמ ג"מ הז . ןלהלש טוריפב תונמוסמ תופסות) דבלב םיירקיעה םינוכדעה םילולכ םודאב :(קוחמ טסקטכ עדימ תורסהו המדקה ליגל תחתמ םירגבתמבו םידליב שומישל תדעוימ הניא הפורתה 18 1 . ?ה Přečtěte si celý dokument